{"doi":"10.1101/2020.06.02.20119578","title":"Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals","abstract":"ABSTRACT Background: Amyloid pathology, which is one of the characteristics of Alzheimer’s disease (AD), results from altered metabolism of the beta-amyloid peptide (Aβ) in terms of synthesis, clearance or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ 1-42 is evident in AD, and the CSF ratio Aβ 40 /Aβ 40 has recently been identified as one of the most reliable diagnostic biomarkers of amyloid pathology. Variations in inter-individual levels of Aβ 1-40 in the CSF have been observed in the past, but their origins remain unclear. In addition, the variation of Aβ 40 in the context of AD studied in several studies has yielded conflicting results. Methods Here, we analyzed the levels of Aβ 1-40 using multicenter data obtained on 2466 samples from six different cohorts in which CSF was collected under standardized protocols, centrifugation and storage conditions. Tau and p-tau(181) concentrations were measured using commercially available in vitro diagnostic immunoassays. Concentrations of CSF Aβ 1-42 and Aβ 1-40 were measured by ELISA, xMAP technology, chemiluminescence immunoassay (CLIA) and mass spectrometry. Statistical analyses were calculated for parametric and non-parametric comparisons, linear regression, correlation and odds ratios. The statistical tests were adjusted for the effects of covariates (age, in particular). Results: Regardless of the analysis method used and the cohorts, a slight but significant age-independent increase in the levels of Aβ 40 in CSF was observed in AD. We also found a strong positive correlation between the levels of Aβ 40 and p-tau(181) in CSF, particularly in control patients. Conclusions: These results indicate that an increase in the baseline level of amyloid peptides, which are associated with an increase in p-tau(181), may be a biological characteristic of AD. This confirms the potential therapeutic value of lowering the baseline levels of Aβ 40 which, being elevated, can be considered a risk factor for the disease.","journal":"medRxiv","year":2020,"id":126950,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9559,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":295707,"name":"Julien Dumurgier","orcid":"0000-0003-2070-9706","position":1,"is_corresponding":false},{"id":315339,"name":"Xavier Ayrignac","orcid":"0000-0003-3834-2981","position":2,"is_corresponding":false},{"id":68070,"name":"Cécilia Marelli","orcid":null,"position":3,"is_corresponding":false},{"id":232612,"name":"Daniel Alcolea","orcid":"0000-0002-3819-3245","position":4,"is_corresponding":false},{"id":232591,"name":"Juan Fortea","orcid":"0000-0002-1340-638X","position":5,"is_corresponding":false},{"id":315340,"name":"Éric Thouvenot","orcid":"0000-0001-8671-7747","position":6,"is_corresponding":false},{"id":315341,"name":"Constance Delaby","orcid":"0000-0002-8606-6814","position":7,"is_corresponding":false},{"id":238272,"name":"Christophe Hirtz","orcid":"0000-0002-7313-0629","position":8,"is_corresponding":false},{"id":315342,"name":"Jérôme Vialaret","orcid":"0000-0002-3730-2366","position":9,"is_corresponding":false},{"id":316237,"name":"Nelly Ginestet","orcid":null,"position":10,"is_corresponding":false},{"id":300792,"name":"Élodie Bouaziz-Amar","orcid":"0000-0003-0880-5826","position":11,"is_corresponding":false},{"id":300793,"name":"Jean Laplanche","orcid":"0000-0003-2836-2903","position":12,"is_corresponding":false},{"id":315343,"name":"Pierre Labauge","orcid":"0000-0001-7759-8555","position":13,"is_corresponding":false},{"id":315344,"name":"Claire Paquet","orcid":"0000-0002-2273-7316","position":14,"is_corresponding":false},{"id":27613,"name":"Alberto Lleó","orcid":"0000-0002-2568-5478","position":15,"is_corresponding":false},{"id":238275,"name":"Audrey Gabelle","orcid":"0000-0002-7648-9194","position":16,"is_corresponding":false},{"id":280227,"name":"for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)","orcid":null,"position":17,"is_corresponding":false},{"id":232610,"name":"Sylvain Lehmann","orcid":"0000-0001-6117-562X","position":0,"is_corresponding":true}],"reference_count":63,"raw_metadata":null,"created_at":"2026-07-18T23:15:27.226519Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}